-
Something wrong with this record ?
Newly identified cerebral microbleeds in patients on anticoagulation for secondary stroke prevention
T. Šrámková, T. Vaňásek, M. Šrámek, P. Janský, K. Benešová, A. Olšerová, S. Kmetonyová, J. Paulasová-Schwabová, M. Klíma, L. Michal, D. Kala, J. Otáhal, L. Mikšík, A. Tomek
Language English Country United States
Document type Journal Article, Observational Study
NLK
PubMed Central
from 2013 to 2 weeks ago
Europe PubMed Central
from 2013
Open Access Digital Library
from 2013-01-01
Open Access Digital Library
from 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1922
- MeSH
- Anticoagulants * adverse effects therapeutic use MeSH
- Cerebral Hemorrhage * chemically induced diagnostic imaging epidemiology MeSH
- Stroke * prevention & control MeSH
- Dabigatran adverse effects therapeutic use MeSH
- Incidence MeSH
- Middle Aged MeSH
- Humans MeSH
- Magnetic Resonance Imaging methods MeSH
- Pyrazoles adverse effects therapeutic use MeSH
- Pyridones adverse effects therapeutic use MeSH
- Secondary Prevention * methods MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
Patients with cardioembolic ischemic stroke are commonly prescribed direct oral anticoagulants (DOACs), such as dabigatran (a direct thrombin inhibitor) and factor Xa inhibitors (e.g., apixaban and rivaroxaban), or warfarin to reduce the risk of recurrent stroke. A major concern in anticoagulant therapy is the risk of intracerebral hemorrhage, which is associated with a high mortality rate. Cerebral microbleeds (MBs), small asymptomatic brain hemorrhages detectable by susceptibility-weighted imaging (SWI) on magnetic resonance imaging (MRI), are associated with increased hemorrhagic stroke risk. This study evaluated the incidence of new MBs during 1 year of anticoagulation therapy in patients after cardioembolic stroke. Patients indicated for anticoagulant therapy after cardioembolic stroke and monitored in the cerebrovascular outpatient clinic of our department underwent brain MRI at baseline and after 1 year of therapy. The occurrence of new MBs was assessed using SWI sequences. MBs were categorized based on location into 3 groups: deep (dMBs), lobar (lMBs), and infratentorial (iMBs). A total of 79 patients were included, 53 of whom were male (67.1%), with a median age of 71 years (IQR: 64-76). The majority of patients (n = 50, 63.3%) were treated with apixaban, 16 patients (20.3%) with dabigatran, and 13 patients (16.5%) with warfarin. Baseline MRI revealed MBs in 17 patients (21.5%), including dMBs in 2, lMBs in 16, and iMBs in 2 patients. Follow-up MRI showed new MBs in 8 patients (10.1%), with new dMBs in 1, lMBs in 5, and iMBs in 4 patients. No statistically significant differences were observed in MBs the incidence of new MBs between anticoagulant groups (P = .912). Over 1 year of anticoagulant therapy, new MBs were detected in 10.1% of patients, predominantly in lobar and infratentorial regions. No differences in the incidence of new MBs were identified between the different anticoagulant groups.
Department of Neurology Jihlava Hospital Czech Republic
Department of Neurology Military University Hospital Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015674
- 003
- CZ-PrNML
- 005
- 20250731091149.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MD.0000000000042011 $2 doi
- 035 __
- $a (PubMed)40419880
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Šrámková, Tereza $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0009000719691832
- 245 10
- $a Newly identified cerebral microbleeds in patients on anticoagulation for secondary stroke prevention / $c T. Šrámková, T. Vaňásek, M. Šrámek, P. Janský, K. Benešová, A. Olšerová, S. Kmetonyová, J. Paulasová-Schwabová, M. Klíma, L. Michal, D. Kala, J. Otáhal, L. Mikšík, A. Tomek
- 520 9_
- $a Patients with cardioembolic ischemic stroke are commonly prescribed direct oral anticoagulants (DOACs), such as dabigatran (a direct thrombin inhibitor) and factor Xa inhibitors (e.g., apixaban and rivaroxaban), or warfarin to reduce the risk of recurrent stroke. A major concern in anticoagulant therapy is the risk of intracerebral hemorrhage, which is associated with a high mortality rate. Cerebral microbleeds (MBs), small asymptomatic brain hemorrhages detectable by susceptibility-weighted imaging (SWI) on magnetic resonance imaging (MRI), are associated with increased hemorrhagic stroke risk. This study evaluated the incidence of new MBs during 1 year of anticoagulation therapy in patients after cardioembolic stroke. Patients indicated for anticoagulant therapy after cardioembolic stroke and monitored in the cerebrovascular outpatient clinic of our department underwent brain MRI at baseline and after 1 year of therapy. The occurrence of new MBs was assessed using SWI sequences. MBs were categorized based on location into 3 groups: deep (dMBs), lobar (lMBs), and infratentorial (iMBs). A total of 79 patients were included, 53 of whom were male (67.1%), with a median age of 71 years (IQR: 64-76). The majority of patients (n = 50, 63.3%) were treated with apixaban, 16 patients (20.3%) with dabigatran, and 13 patients (16.5%) with warfarin. Baseline MRI revealed MBs in 17 patients (21.5%), including dMBs in 2, lMBs in 16, and iMBs in 2 patients. Follow-up MRI showed new MBs in 8 patients (10.1%), with new dMBs in 1, lMBs in 5, and iMBs in 4 patients. No statistically significant differences were observed in MBs the incidence of new MBs between anticoagulant groups (P = .912). Over 1 year of anticoagulant therapy, new MBs were detected in 10.1% of patients, predominantly in lobar and infratentorial regions. No differences in the incidence of new MBs were identified between the different anticoagulant groups.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a cerebrální krvácení $x chemicky indukované $x diagnostické zobrazování $x epidemiologie $7 D002543
- 650 12
- $a antikoagulancia $x škodlivé účinky $x terapeutické užití $7 D000925
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a magnetická rezonanční tomografie $x metody $7 D008279
- 650 12
- $a sekundární prevence $x metody $7 D055502
- 650 _2
- $a dabigatran $x škodlivé účinky $x terapeutické užití $7 D000069604
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a pyridony $x škodlivé účinky $x terapeutické užití $7 D011728
- 650 12
- $a cévní mozková příhoda $x prevence a kontrola $7 D020521
- 650 _2
- $a pyrazoly $x škodlivé účinky $x terapeutické užití $7 D011720
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 700 1_
- $a Vaňásek, Tomáš $u Department of Radiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0009000242762321
- 700 1_
- $a Šrámek, Martin $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $u Department of Neurology, Military University Hospital Prague, Czech Republic $1 https://orcid.org/0000000255199876 $7 xx0071056
- 700 1_
- $a Janský, Petr $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000331590958
- 700 1_
- $a Benešová, Kateřina $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0009000793698434
- 700 1_
- $a Olšerová, Anna $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000230571387
- 700 1_
- $a Kmetonyová, Silvia $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000347653378
- 700 1_
- $a Paulasová-Schwabová, Jaroslava $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000284658269
- 700 1_
- $a Klíma, Michal $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $u Department of Neurology, Jihlava Hospital, Czech Republic
- 700 1_
- $a Michal, Lukáš $u Department of Pathophysiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0009000818715385
- 700 1_
- $a Kala, David $u Department of Pathophysiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000230101174
- 700 1_
- $a Otáhal, Jakub $u Department of Pathophysiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic $1 https://orcid.org/0000000159445803 $7 xx0105144
- 700 1_
- $a Mikšík, Lukáš $u Department of Radiology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Tomek, Aleš $u Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital Motol, Prague, Czech Republic
- 773 0_
- $w MED00012436 $t Medicine $x 1536-5964 $g Roč. 104, č. 21 (2025), s. e42011
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40419880 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091144 $b ABA008
- 999 __
- $a ok $b bmc $g 2366497 $s 1252799
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 104 $c 21 $d e42011 $e 20250523 $i 1536-5964 $m Medicine $n Medicine (Baltimore) $x MED00012436
- LZP __
- $a Pubmed-20250708